CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CRESTAR project focuses on developing genetic tests to identify patients with treatment-resistant schizophrenia. By analyzing genetic and epigenetic data, the project aims to predict responses to antipsychotic medications and potential side effects, ultimately improving treatment strategies for affected individuals…
Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden.
First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics.
The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to be effective in TRS, about half of TRS patients are also resistant to clozapine. CRESTAR is an SME-dr…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Iceland, Reykjavik
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
LANDSPITALI UNIVERSITY HOSPITAL
Iceland, Reykjavik
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, MUNCHEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Cardiff
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
